Julie Rubinstein Sells 19,060 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Key Points

• Julie Rubinstein, Adaptive's COO, executed multiple pre-arranged Rule 10b5-1 sales in March–April (including 19,060 shares on Apr 10 at $12.77 and a 141,583-share sale on Mar 11), cutting her stake by about 4.29% to 425,512 shares (≈$5.43M).
• ADPT stock jumped about 10.5% to $14.13 on heavy volume after the company reported a quarterly beat—revenue up 51% and EPS above estimates—but it remains unprofitable with negative margins and ROE, and analysts' consensus is a "Moderate Buy" with a $18.25 target.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) COO Julie Rubinstein sold 19,060 shares of the stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $12.77, for a total transaction of $243,396.20. Following the sale, the chief operating officer directly owned 425,512 shares of the company's stock, valued at approximately $5,433,788.24. This represents a 4.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

• On Monday, April 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.15, for a total transaction of $250,639.00.
• On Tuesday, April 7th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.56, for a total transaction of $258,453.60.
• On Wednesday, April 8th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.83, for a total transaction of $458,855.03.
• On Wednesday, April 1st, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.45, for a total transaction of $275,417.00.
• On Monday, March 23rd, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.83, for a total transaction of $263,599.80.
• On Friday, March 20th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.37, for a total transaction of $254,832.20.
• On Wednesday, March 18th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.18, for a total transaction of $251,210.80.
• On Monday, March 16th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.41, for a total transaction of $255,594.60.
• On Wednesday, March 11th, Julie Rubinstein sold 141,583 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.29, for a total transaction of $1,881,638.07.
• On Friday, March 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $12.96, for a total transaction of $247,017.60.

Adaptive Biotechnologies Trading Up 10.5%

ADPT stock traded up $1.34 during midday trading on Monday, reaching $14.13. The company had a trading volume of 3,126,145 shares, compared to its average volume of 1,989,528. Adaptive Biotechnologies Corporation has a 1 year low of $6.77 and a 1 year high of $20.76. The company has a market capitalization of $2.18 billion, a P/E ratio of -35.32 and a beta of 2.29. The company has a 50 day moving average of $14.87 and a two-hundred day moving average of $15.99.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last released its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.10. The business had revenue of $71.68 million for the quarter, compared to the consensus estimate of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. Adaptive Biotechnologies's revenue for the quarter was up 51.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.23) EPS. On average, sell-side analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on ADPT. Piper Sandler set a $21.00 price target on shares of Adaptive Biotechnologies in a report on Friday, February 6th. TD Cowen restated a "buy" rating on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Wall Street Zen downgraded shares of Adaptive Biotechnologies from a "buy" rating to a "hold" rating in a report on Saturday, March 7th. JPMorgan Chase & Co. raised their price target on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an "overweight" rating in a report on Friday, February 6th. Finally, BTIG Research raised their price target on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a "buy" rating in a report on Friday, February 6th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $18.25.

Hedge Funds Weigh In On Adaptive Biotechnologies

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Allianz Asset Management GmbH boosted its position in Adaptive Biotechnologies by 305.8% in the third quarter. Allianz Asset Management GmbH now owns 321,774 shares of the company's stock valued at $4,814,000 after buying an additional 242,474 shares in the last quarter. SG Americas Securities LLC boosted its position in Adaptive Biotechnologies by 82.5% in the third quarter. SG Americas Securities LLC now owns 68,113 shares of the company's stock valued at $1,019,000 after buying an additional 30,785 shares in the last quarter. Affinity Wealth Management LLC acquired a new position in Adaptive Biotechnologies in the third quarter valued at about $4,541,000. Aristotle Atlantic Partners LLC boosted its position in Adaptive Biotechnologies by 8.6% in the third quarter. Aristotle Atlantic Partners LLC now owns 3,126,719 shares of the company's stock valued at $46,776,000 after buying an additional 247,402 shares in the last quarter. Finally, Lisanti Capital Growth LLC acquired a new position in Adaptive Biotechnologies in the third quarter valued at about $4,476,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.